evaluations+economics

The debate over a budget reconciliation package in the coming weeks, and possibly months, is likely to focus heavily on the savings to Medicare, which can be used to expand Medicare benefits and fund other health care priorities.

The Institute for Clinical and Economic Review (ICER) has released a Final Evidence Report assessing the comparative clinical effectiveness and value of aducanumab (Aduhelm, Biogen) for the treatment of Alzheimer’s disease.

Stunning reversals, surprise delays and controversial approvals are the order of the day at the FDA lately — and doctors have had enough.

A preponderance of evidence proves the virus that caused the COVID-19 pandemic leaked from a Chinese research facility, said a report by U.S. Republicans released on Monday.

High biologic drug prices have placed substantial strain on the US health care system.

France has a single-payer health insurance system that has the authority to impose pharmaceutical price reductions but relies on decentralized market negotiations between hospitals and manufacturers to establish prices for injected and infused biologics.

The continuing launch of innovative but high-price drugs has intensified efforts by payers to manage use and spending and by pharmaceutical manufacturers to support patient access and sales.

Criticisms of the US Food and Drug Administration’s accelerated approval process have resurfaced after the recent approval of aducanumab (Aduhelm) for dementia.

The world is at risk of losing hard-won gains in fighting COVID-19 as the highly transmissible Delta variant spreads.

Health Evidence Network Synthesis Report 73

One that recently hit the market — winning Food and Drug Administration approval in June — is Novo Nordisk’s Wegovy, a higher-dose version of the company’s injectable diabetes drug, Ozempic.

An estimated 50 million inpatient surgical procedures occur each year in the United States, at a cost of $175 billion.

Real-world data shows similar safety profile for Vaxzevria and mRNA-based jabs.

Our findings beg the question: Why do these disparities exist? And what can be done to address them?

Researchers attributed the estimated increase to a rise in cases among younger women.